The prosthetic business grew organically by 3 percent in the first quarter of the year at Icelandic orthopedics manufacturer Össur. This is a solid improvement compared with the same quarter last year, during which the same business leg shrunk by 4 percent.
The firm's interim report shows overall progress in all business areas.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.